Kelly Patrick F. 4
4 · Forma Therapeutics Holdings, Inc., · Filed Jun 24, 2020
Insider Transaction Report
Form 4
Kelly Patrick F.
SVP, Chief Medical Officer
Transactions
- Purchase
Common Stock
2020-06-23+42,959→ 42,959 total - Sale
Enterprise 4 Junior Stock
2020-06-23−5,844→ 0 total - Sale
Enterprise 3 Junior Stock
2020-06-23−17,533→ 0 total - Sale
Enterprise 6 Junior Stock
2020-06-23−40,911→ 0 total
Footnotes (1)
- [F1]Effective immediately upon the closing of the Registrant's initial public offering on June 23, 2020, the reporting person converted (i) 17,533 shares of Enterprise 3 Junior Stock at a conversion rate of 0.7822 shares of common stock per one share of Enterprise 3 Junior Stock, (ii) 5,844 shares of Enterprise 4 Junior Stock at a conversion rate of 0.7585 shares of common stock per one share of Enterprise 4 Junior Stock and (iii) 40,911 shares of Enterprise 6 Junior Stock at a conversion rate of 0.6065 shares of common stock per one share of Enterprise 6 Junior Stock, resulting in his acquisition of 42,959 shares of common stock.